Wasteful and Inappropriate Service Reduction Model (WISeR)

Analysis updated November 9, 2026

Strategic questions for your team

Which of our high-volume procedures across the 13 active WISeR service categories — including skin and tissue substitutes, spinal cord stimulators, cervical fusion, epidural steroid injections, sacral nerve stimulation, and hypoglossal nerve stimulation — are billed in AZ, NJ, OH, OK, TX, or WA, and what is our annual Medicare FFS revenue at risk if our current documentation practices cannot achieve the provisional affirmation threshold required to avoid pre-payment medical review for those claims?
Given that WISeR participants are paid a percentage of averted expenditures calculated using average claim-level payments (not just line-item CPT/HCPCS codes) for the prior 12 months, and that non-affirmations trigger full claim suspension — not just denial of a single code — what is our realistic total revenue exposure per service category, and do we have the cash-flow reserves to absorb payment holds of up to 120 days plus the one-year clawback window on contested non-affirmations?
Are our clinical documentation workflows — particularly for the mandatory pre-authorization data elements in Table 1 (MBI, NPI, PTAN, CPT/HCPCS codes, diagnosis codes, anticipated POS, units of service) and the service-specific requirements in Section 6.2 (e.g., multidisciplinary team evaluation for spinal cord stimulators, failure of at least four prior treatments for VNS/TRD, polysomnography for phrenic nerve stimulators) — complete, retrievable, and submittable within the 3-calendar-day standard review window, and do we have a designated workflow owner accountable for each of the 13 active service categories?
What is our current prior authorization affirmation rate for WISeR-covered services with the relevant MACs (JH/JL Novitas, J15/CGS, JF/Noridian), and can we realistically achieve and sustain the 90% provisional affirmation threshold needed to qualify for the 'gold card' exemption — which, once granted quarterly and maintained through annual ADR reviews of no more than 10 records, would eliminate prior authorization and pre-payment review burden entirely for compliant individual providers at the NPI level?
Have we mapped every WISeR Select Item and Service in Appendix A against our current EHR documentation templates and revenue cycle workflows to confirm we can (a) submit prior authorization requests to the correct state-assigned participant (e.g., Cohere Health for TX, Genzeon for NJ, Humata for OK, Innovaccer for OH, Virtix for WA, Zyter for AZ) via their specific portals, fax numbers, or email addresses before the service date, (b) include the UTN on every subsequent claim regardless of affirmation status, and (c) flag and hold claims for affirmed expedited services until the UTN is issued — all without disrupting existing scheduling and billing cycles?
For services subject to WISeR pre-payment medical review (i.e., claims submitted without prior authorization), have we assessed the operational burden of responding to documentation requests within the 45-calendar-day response window, and do our medical records, coding, and compliance teams have sufficient capacity to pull and submit service-specific clinical documentation — such as standing X-rays and MRI results for knee arthroscopy, or failed-conservative-treatment records for cervical fusion — across potentially high claim volumes simultaneously?
What is our legal and compliance exposure if AI-generated affirmation recommendations from a WISeR participant are later overturned on appeal or audit, and have we consulted with counsel on whether our organization's agreement to participate in or be subject to the WISeR review process affects our liability under the False Claims Act, given that the RFA explicitly states all applicable fraud and abuse laws — including Sections 1128A, 1128B, and 1877 of the Social Security Act — remain fully in force and that no FWA law waivers have been granted under this model?
How will WISeR interact with our existing value-based care arrangements — including ACO REACH, MSSP, or bundled payment models — given that the RFA explicitly states WISeR does not change claims payment rules, does not qualify as an Advanced APM or MIPS APM, and has no beneficiary assignment or total cost of care accountability, but that non-affirmations for WISeR-covered services could reduce procedure volumes that currently generate both fee-for-service revenue and episode-based or shared-savings reconciliation payments?
For providers in our group who are currently under Unified Program Integrity Contractor (UPIC) review — who are explicitly excluded from WISeR per Section 1.2 of the Operational Guide (Version 7.0, updated July 24, 2026) — have we identified all affected NPIs and confirmed they are following the standard MAC billing process without submitting WISeR prior authorization requests, to avoid dismissals or compliance complications that could escalate their UPIC review status?
What is our competitive positioning strategy for the post-2031 period, given that CMS has explicitly stated WISeR is designed to serve as a 'roadmap for incorporating more private sector innovations into CMS operations' and that favorable evaluation results under Section 1115A could trigger national expansion — meaning that prior authorization infrastructure, documentation discipline, and gold-card exemption status built during the 2026–2031 model period may become permanent competitive advantages or liabilities relative to peer health systems once the model scales?
In light of emerging reports that WISeR's AI-driven prior authorization process has left patients waiting months for care, what is our patient relations and care coordination strategy for managing delayed or suspended authorizations — including how we communicate with beneficiaries about review timelines, identify clinically urgent cases requiring expedited review, and mitigate downstream adverse outcomes or liability exposure arising from AI-generated non-affirmations that later prove incorrect?
Given that external commentary and expert discussion of WISeR is intensifying — including clinical expert forums on its impact on utilization management broadly — have we assessed how WISeR's AI review methodology, non-affirmation patterns, and appeals outcomes in our service categories compare to commercial prior authorization benchmarks, and do we have a structured process to monitor and challenge algorithmic decisions that appear to deviate from evidence-based clinical standards?

Traps and concerns

Perverse Denial Incentive Distorts Clinical Judgment
WISeR participants are paid a percentage of expenditures averted through non-affirmations — a pure contingency fee structure. This creates a direct financial incentive to deny borderline cases, because every non-affirmed claim that is not subsequently resubmitted and affirmed within 120 calendar days generates revenue for the participant. The 120-day window means a participant profits even from denials that are eventually overturned after that window closes. For providers, this means prior authorization decisions may systematically skew toward denial for high-cost services like cervical fusion or hypoglossal nerve stimulators (which can carry average claim payments in the tens of thousands of dollars), regardless of clinical merit. Providers should expect non-affirmation rates higher than those seen under traditional MAC review, and should budget for the administrative cost of unlimited resubmissions and peer-to-peer reviews, which the model permits but does not compensate providers for pursuing.
Baseline Denial Rate Discount Creates Reconciliation Opacity
The payment methodology applies a 'baseline discount' to participant savings: CMS calculates the historical MAC medical necessity denial rate by item and region, then reduces participant payments by that rate to avoid paying for denials the MAC would have captured anyway. For example, if 3% of skin substitute claims were historically denied by the MAC, each WISeR non-affirmation payment is discounted by 3%. Providers face a mirror-image risk: the baseline is calculated using pre-implementation claims data that may not reflect their specific patient population or documentation practices. If CMS sets an inflated baseline for a service category, participants have less financial incentive to process affirmations quickly, potentially slowing turnaround on clinically appropriate requests. Providers have no visibility into how the baseline is calculated, making it impossible to predict which service categories will face the most aggressive review without access to regional MAC denial rate data.
LCD Variability Across Jurisdictions Undermines Compliance Consistency
Thirteen of the WISeR service categories are governed by Local Coverage Determinations (LCDs) rather than National Coverage Determinations (NCDs), meaning coverage criteria differ by MAC jurisdiction. A multi-state provider group operating in Texas (JH/Novitas), Ohio (J15/CGS), and Washington (JF/Noridian) faces three different LCD frameworks for services like epidural steroid injections (L39015, L39242, L36920 across jurisdictions) and percutaneous vertebral augmentation (L34106, L38201, L35130). The model explicitly states that a service is only included in WISeR if the relevant LCD is active in that region — meaning the operative scope shifts if a MAC retires or updates an LCD mid-performance year. The Operational Guide (Version 7.0, July 24, 2026) already reflects multiple LCD number revisions from the original RFA (e.g., L39242 became L39240 for epidural steroid injections). Providers who hard-code documentation templates to original LCD numbers risk submitting non-compliant prior authorization requests, triggering dismissals and pre-payment review exposure.
UPIC Review Exclusion Creates Sudden Mid-Cycle Lockout
Version 7.0 of the Provider and Supplier Operational Guide (July 24, 2026) explicitly excludes providers and suppliers under Unified Program Integrity Contractor (UPIC) review from the WISeR model. This means that a provider who is placed under UPIC review after having established an exemption ('gold card') status — which requires at least 10 prior authorization requests and a 90% or higher affirmation rate — loses that exemption immediately and without the 60-day advance notice that applies to standard exemption revocations. For high-volume providers in specialties like wound care or interventional pain management, a mid-year UPIC designation triggers mandatory pre-payment review on all WISeR services, halting cash flow on claims until documentation is submitted (within 45 calendar days of the documentation request) and reviewed. Providers who receive a significant share of revenue from WISeR-covered services in affected states face acute accounts receivable disruption with no clear reinstatement pathway described in the model documentation.
FedRAMP/FISMA Compliance Gap Triggers Immediate Data Breach Liability
Each of the six WISeR participants must maintain FedRAMP-certified workflows, comply with FISMA, follow CMS IS2P2 and Acceptable Risk Safeguards, and report any data or security incident to the CMS Service Desk within one hour of discovery (CMS Risk Management Handbook Chapter 8). These participants handle protected health information (PHI) under HIPAA Business Associate Agreements with both CMS and the MACs. For providers and suppliers, the operational risk is that a security incident at a WISeR participant — for example, Innovaccer Inc. in Ohio or Cohere Health in Texas — could result in delayed processing of all pending prior authorization requests across that jurisdiction while the participant remediates the breach. Because each jurisdiction has exactly one assigned participant with no backup entity, a compliance-driven suspension of a participant's operations would leave all WISeR-covered providers in that state without a functional prior authorization pathway, forcing every claim into pre-payment review until the participant is restored or replaced.
120-Day UTN Expiration Creates Surgical Scheduling Cliffs
Provisional affirmation decisions are valid for exactly 120 calendar days from the decision date. For services with long pre-surgical preparation timelines — such as sacral nerve stimulators for urinary incontinence (which require a documented trial period before permanent implantation) or hypoglossal nerve stimulators for obstructive sleep apnea (which involve multi-step evaluation protocols) — the 120-day window may expire before the permanent implantation can be scheduled, particularly for high-volume WISeR jurisdictions like Texas and Ohio where capacity constraints or beneficiary complexity extend preparation timelines. If the affirmation lapses, the provider must submit an entirely new prior authorization request, restarting the 3-calendar-day standard review clock and potentially creating a gap in coverage continuity. For ASC and hospital outpatient settings, where OR block time is allocated months in advance, an expired UTN can result in a cancelled procedure date and both direct revenue loss and patient access harm. Early implementation reports indicate patients are experiencing delays of months waiting for care under WISeR, suggesting that UTN expiration cliffs are a live operational problem and not merely a theoretical risk.
Clawback Mechanism Exposes Providers to Retroactive Denial After Service Delivery
The payment design specifies that if a provider furnishes a non-affirmed service, submits the claim, and successfully appeals the MAC's payment denial, CMS claws back the model payment previously issued to the WISeR participant for that non-affirmation. While this protects the participant from double payment, it creates a perverse operational dynamic for providers: the appeals process (governed by 42 C.F.R. Part 405, Subpart I) can take months or years to resolve, during which the provider has already absorbed the cost of delivering the service. For high-cost items like cervical fusion or spinal cord stimulator implantation — where total claim payments (not just the primary procedure code, but all associated secondary and add-on services) are used in the savings calculation — a provider who proceeds after a non-affirmation and eventually wins on appeal has, in effect, extended an interest-free loan to Medicare for the duration of the appeals process. Providers in the six WISeR states should implement real-time tracking of all non-affirmed UTNs and associated claims to ensure appeals are filed within Medicare's mandatory appeal windows and to quantify the accounts receivable exposure from non-affirmed claims in progress.
AI-Driven Review Introduces Algorithmic Denial Risk Without Adequate Transparency or Recourse
WISeR participants use AI-assisted clinical decision tools to process prior authorization requests, raising concerns — reported by clinical experts and trade press — that algorithmic review may apply coverage criteria in ways that are opaque to providers and inconsistent with individualized clinical judgment. Unlike human reviewers, AI systems cannot readily account for patient-specific comorbidities, functional status, or the kind of documented medical frailty that a treating clinician would present in a peer-to-peer review. Because the model does not require participants to disclose the AI logic underlying a non-affirmation, providers have no basis to challenge the algorithmic rationale through the peer-to-peer process — they can only resubmit documentation, which the AI may evaluate using the same logic. This risk is compounded for medically complex or frail patients where clinical necessity is inherently fact-intensive. Providers should document patient-specific clinical context exhaustively in every initial submission, anticipating that algorithmic review will not infer necessity from diagnoses alone, and should escalate to peer-to-peer immediately upon non-affirmation rather than relying on resubmission to resolve algorithmically generated denials.